ストックスクリーナーアプリを入手
10.42
1.56%
0.16
プレマーケット:
10.99
0.57
+5.47%
前日終値:
$10.26
開ける：
$10.39
24時間の取引高:
342.36K
Relative Volume:
0.67
時価総額：
$606.73M
収益：
-
当期純損益:
$-153.16M
株価収益率:
-2.8238
EPS:
-3.69
ネットキャッシュフロー:
$-134.48M
1週間 パフォーマンス:
+4.10%
1か月 パフォーマンス:
-10.17%
6か月 パフォーマンス:
-43.03%
1年 パフォーマンス:
-9.47%
1日の値動き範囲:
$10.26
$10.52
1週間の範囲:
$9.83
$10.52
52週間の値動き範囲:
$9.5005
$30.19
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
CGEM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
10.42 | 606.73M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-05-01 | 開始されました | Stifel | Buy |
| 2024-04-15 | 開始されました | William Blair | Outperform |
| 2024-02-15 | 開始されました | Wedbush | Outperform |
| 2023-06-15 | 開始されました | TD Cowen | Outperform |
| 2022-11-21 | 開始されました | BTIG Research | Buy |
| 2021-04-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | 開始されました | Evercore ISI | Outperform |
| 2021-02-02 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-02-02 | 開始されました | SVB Leerink | Outperform |
| 2021-02-01 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Cullinan Therapeutics Inc (CGEM) 最新ニュース
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of “Buy” from Analysts - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Hits New 52-Week LowHere's What Happened - MarketBeat
Harbor Capital Advisors Inc. Purchases 9,385 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 7.3%Should You Sell? - MarketBeat
Cullinan Therapeutics’ CLN-978 And Zipalertinib Look Promising In NSCLC (NASDAQ:CGEM) - Seeking Alpha
Cullinan Therapeutics: Casting A Wide Net With Their Pipeline (NASDAQ:CGEM) - Seeking Alpha
Jennifer Michaelson Sells 4,000 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock - MarketBeat
Cullinan Therapeutics' chief scientific officer sells shares worth $50,040 - Investing.com
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 5.4%What's Next? - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Large Growth in Short Interest - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap UpWhat's Next? - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Significant Increase in Short Interest - MarketBeat
Don't Ignore The Insider Selling In Cullinan Therapeutics - Simply Wall St
Financial Comparison: Genfit (NASDAQ:GNFT) vs. Cullinan Therapeutics (NASDAQ:CGEM) - Defense World
Geode Capital Management LLC Acquires 231,935 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Geode Capital Management LLC Buys 231,935 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics CEO sells shares worth $99,708 - Investing.com India
Insider Selling: Cullinan Therapeutics, Inc. (NASDAQ:CGEM) CEO Sells 8,400 Shares of Stock - MarketBeat
Cullinan Therapeutics CEO sells shares worth $99,708 By Investing.com - Investing.com South Africa
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 2.9%Should You Sell? - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Recommendation of “Buy” by Analysts - Defense World
Barclays PLC Acquires 51,300 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Trading 5.6% Higher – Here’s Why - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by State Street Corp - Defense World
State Street Corp Increases Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Sells $53,547.13 in Stock - MarketBeat
Cullinan Therapeutics' chief medical officer sells $52,851 in stock By Investing.com - Investing.com Australia
Cullinan Therapeutics' chief medical officer sells $52,851 in stock - Investing.com
Cullinan Therapeutics chief scientific officer sells $53,547 in stock - Investing.com
Cullinan therapeutics chief legal officer sells $39,729 in stock - Investing.com India
Cullinan Therapeutics chief scientific officer sells $53,547 in stock By Investing.com - Investing.com UK
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 5.6%What's Next? - MarketBeat
Fmr LLC Purchases 19,681 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Franklin Resources Inc. Sells 252,868 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 4%Here's Why - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.19 Million Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Insider Selling: Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Sells 3,489 Shares of Stock - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Bought by The Manufacturers Life Insurance Company - Defense World
Charles Schwab Investment Management Inc. Boosts Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Purchased by RTW Investments LP - MarketBeat
Patient Square Capital LP Acquires New Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Bought by Holocene Advisors LP - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by Walleye Capital LLC - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by Braidwell LP - MarketBeat
Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Price Target at $31.67 - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives $31.67 Average Target Price from Brokerages - MarketBeat
Cullinan Therapeutics Inc (CGEM) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):